A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386

Hypertension and Dyslipidemia Clinical Trial

Official title:

An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-386 With Co-administration of D012, D326, and D337 in Healthy Adult Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04673864
• Other study ID #: A83_06BE1919
• Status: Completed
• Phase: Phase 1
• Start date: January 17, 2021
• Est. completion date: March 30, 2021

Study information

• Verified date: July 2021
• Source: Chong Kun Dang Pharmaceutical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386

Description:

An open label, randomized, single dose, 2-sequence, 4-period, cross-over clinical trial to evaluate the pharmacokinetics and tolerability of CKD-386 with co-administration of D012, D326, and D337 in healthy adult volunteers

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: March 30, 2021
• Est. primary completion date: March 4, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Healthy adult volunteers aged = 19 years

2. Weight =50kg (man) or 45kg (woman), with calculated body mass index (BMI) of 18 to 30 kg/m2

3. Those who meet the blood pressure criteria during screening tests:

• Systolic Blood Pressure: 90 to 139 mmHg

• Diastolic Blood Pressure: 60 to 89 mmHg

4. Those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings.

5. Those who are eligible for clinical trials based on laboratory(hematology, blood chemistry, serology, urology) and 12-lead ECG results at screening.

6. Those who agree to contraception during the participation of clinical trial.

7. Individuals who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.

Exclusion Criteria:

1. Those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs.

2. Those who take barbiturate and any related drugs which may cause induction or inhibition of drug metabolism within 1 month before the first administration of investigational products.

3. Those who donated whole blood or apheresis within 2 months or 1 month respectfully, or received blood transfusion within a month.

4. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery.

5. Those who exceed an alcohol and cigarette consumption than below criteria

• Alcohol: Man_21 glasses/week, Woman_14 glasses/week (1 glass:

Soju 50mL, Wine 30mL, or beer 250mL)

• Smoking: 20 cigarettes/day

6. Patients with the following diseases

• Patients with hypersensitivity to the main constituents or components of the investigational drug

• Severe hepatic impairment, biliary atresia or cholestasis

• Patients with hereditary angioedema or with a history of angioedema in the treatment of ACE inhibitors or angiotensin II receptor antagonists

• Diabetes mellitus

• Patients with moderate to severe renal impairment [glomerular filtration rate (eGFR) <60 mL / min / 1.73m^2]

• Renal vascular hypertension patients

• Patients with active liver disease, including unexplained persistent serum transaminase elevations or elevated serum transaminase elevations greater than three times the normal upper limit

• Patients with myopathy or have a history of family or genetic history of myopathy

• Hypothyroidism

• If you have a history of muscle toxicity for other HMG-CoA converting enzymes or fibrate class drugs

7. Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption.

8. Those who are deemed insufficient to participate in this clinical study by investigators.

9. Woman who are pregnant or breastfeeding.

Related Conditions & MeSH terms

• Dyslipidemias
• Hypertension and Dyslipidemia

Intervention

Drug:
• CKD-386
QD, PO
• D012, D326, D337
QD, PO

Locations

Country	Name	City	State
Korea, Republic of	H Plus Yangji Hospital	Seoul	Gwanak-gu

Sponsors (1)

Lead Sponsor	Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUCt of CKD-386	AUCt: Area under the concentration-time curve from time zero to time	Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 hours
Primary	Cmax of CKD-386	Maximum plasma concentration of the drug	Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 hours
Secondary	AUCinf of CKD-386	AUCinf: Area under the concentration-time curve from zero up to 8	Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 hours
Secondary	Tmax of CKD-386	Tmax: Time to maximum plasma concentration	Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 hours
Secondary	AUCt/AUCinf of CKD-386	AUCt/AUCinf	Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 hours
Secondary	T1/2 of CKD-386	T1/2: Terminal elimination half-life	Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 hours